TI
MRSN

Trexquant Investment’s Mersana Therapeutics MRSN Stock Holding History

Trexquant Investment’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,218
Closed -$331K – 1658
2023
Q1 		$331K Sell
3,218
-3,091
-49% -$434K 0.01% 1161
2022
Q4 		$924K Buy
6,309
+2,511
+66% +$424K 0.03% 675
2022
Q3 		$642K Buy
+3,798
New +$617K 0.02% 704
2022
Q1 		– Sell
-1,653
Closed -$257K – 1601
2021
Q4 		$257K Buy
+1,653
New +$322K 0.02% 1011

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Trexquant Investment's MRSN Position: Q2 2023 in Review

Trexquant Investment sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 3,218 shares — an estimated $331K sold.

Trexquant Investment first reported a position in MRSN in Q4 2021 and held it in 4 quarters. The position peaked at $924K in Q4 2022. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Trexquant Investment reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Trexquant Investment sold 3,218 Mersana Therapeutics shares in Q2 2023, an estimated $331K.
  • Trexquant Investment first reported a position in Mersana Therapeutics in Q4 2021 and held it in 4 quarters.
  • Trexquant Investment's Mersana Therapeutics position peaked at $924K in Q4 2022.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Trexquant Investment's 13F filing for Q2 2023, filed 11 Aug 2023.